A paradigm shift in cell-free approach: the emerging role of MSCs-derived exosomes in regenerative medicine

Journal of Translational Medicine

Heshu Sulaiman Rahman¹  Marischa Elveny²  Ali Hassanzadeh³  Soudeh Moghadasi⁴  Walid Kamal Abdelbasset⁵  Faroogh Marofi⁶  Siavash Shariatzadeh⁷  Abduladheem Turki Jalil⁸  Wanich Suksatan⁹  Mostafa Jarahian^1,10  Farahnaz Behzad^1,11  Alexei Valerievich Yumashev^1,12  Roza Motavalli^1,13  Yashwant Pathak^1,14 

[1] College of Medicine, University of Sulaimani;DS & CI Research Group, Universitas Sumatera Utara;Department of Applied Cell Sciences, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences;Department of Biochemistry and Molecular Biology, School of Medicine, Shahid Sadoughi University of Medical Sciences;Department of Health and Rehabilitation Sciences, College of Applied Medical Sciences, Prince Sattam Bin Abdulaziz University;Department of Hematology, Faculty of Medicine, Tabriz University of Medical Sciences;Department of Pharmacology, School of Medicine, Shahid Beheshti University of Medical Sciences;Faculty of Biology and Ecology, Yanka Kupala State University of Grodno;Faculty of Nursing, HRH Princess Chulabhorn College of Medical Science, Chulabhorn Royal Academy;German Cancer Research Center, Toxicology and Chemotherapy Unit (G401);Research Institute of Bioscience and Biotechnology, University of Tabriz;Sechenov First Moscow State Medical University;Stem Cell Research Center, Tabriz University of Medical Sciences;Taneja College of Pharmacy, University of South Florida;

关键词: Mesenchymal stem/stromal cells (MSCs);    Exosomes;    Regenerative medicine;    Micro-RNAs (miRNAs);   

DOI  :  10.1186/s12967-021-02980-6

来源: DOAJ

【 摘 要 】

Abstract Recently, mesenchymal stem/stromal cells (MSCs) due to their pro-angiogenic, anti-apoptotic, and immunoregulatory competencies along with fewer ethical issues are presented as a rational strategy for regenerative medicine. Current reports have signified that the pleiotropic effects of MSCs are not related to their differentiation potentials, but rather are exerted through the release of soluble paracrine molecules. Being nano-sized, non-toxic, biocompatible, barely immunogenic, and owning targeting capability and organotropism, exosomes are considered nanocarriers for their possible use in diagnosis and therapy. Exosomes convey functional molecules such as long non-coding RNAs (lncRNAs) and micro-RNAs (miRNAs), proteins (e.g., chemokine and cytokine), and lipids from MSCs to the target cells. They participate in intercellular interaction procedures and enable the repair of damaged or diseased tissues and organs. Findings have evidenced that exosomes alone are liable for the beneficial influences of MSCs in a myriad of experimental models, suggesting that MSC- exosomes can be utilized to establish a novel cell-free therapeutic strategy for the treatment of varied human disorders, encompassing myocardial infarction (MI), CNS-related disorders, musculoskeletal disorders (e.g. arthritis), kidney diseases, liver diseases, lung diseases, as well as cutaneous wounds. Importantly, compared with MSCs, MSC- exosomes serve more steady entities and reduced safety risks concerning the injection of live cells, such as microvasculature occlusion risk. In the current review, we will discuss the therapeutic potential of MSC- exosomes as an innovative approach in the context of regenerative medicine and highlight the recent knowledge on MSC- exosomes in translational medicine, focusing on in vivo researches.

【 授权许可】

Unknown